Book Cover
Home  |   Healthcare   |  Respiratory Devices Market

Respiratory Devices Market Size, Share, Growth, and Industry Analysis, By Type (Respiratory Positive Airway Pressure Devices, Respiratory Mask, Respiratory Ventilators, Respiratory Oxygen Concentrators, Respiratory Inhalers, Respiratory Resuscitators, Respiratory Nebulizers, Respiratory Humidifiers, Respiratory Oxygen Hoods), By Application (Hospitals, Home Care, Other End-Users), Regional Insights and Forecast to 2035

Trust Icon
1000+
GLOBAL LEADERS TRUST US

Respiratory Devices Market Overview

The global Respiratory Devices Market is projected to experience sustained growth from USD 31755.97 Million in 2026 to USD 56211.56 Million by 2035, exhibiting a CAGR of 6.55% during the forecast period 2026-2035.

The global Respiratory Devices Market is expanding through increasing demand for respiratory disease management, sleep-disordered breathing treatment, and critical care infrastructure. Respiratory Positive Airway Pressure Devices represent an estimated 24% of modeled product demand, supported by sleep apnea therapy and growing home-based treatment requirements. These segment shares are analytical estimates rather than independently verified market measurements. Respiratory equipment encompasses devices used to support ventilation, deliver oxygen, administer inhaled medicines, maintain airway humidity, and assist breathing during emergencies. Hospitals increasingly emphasize dependable ventilators and oxygen delivery systems, while home care providers prioritize comfortable interfaces, portability, and manageable therapy settings.

The USA Respiratory Devices Market benefits from established respiratory care infrastructure, demand for sleep apnea treatment, and increasing adoption of home respiratory equipment. North America accounts for an estimated 36% of modeled global demand, reflecting substantial hospital procurement and home therapy requirements. Respiratory devices are used across intensive care units, emergency departments, outpatient services, and appropriately supervised home treatment programs. During February 2026, ResMed Inc. introduced its AirTouch F30i Comfort full-face CPAP mask in the United States, emphasizing patient comfort and sustained therapy use. Vapotherm Inc. also obtained regulatory clearance for an expanded patient circuit supporting its high-velocity respiratory therapy system. American healthcare organizations increasingly evaluate device interoperability, clinical effectiveness, infection prevention, and long-term service support. 

Global Respiratory Devices Market Size, 2035 (USD Million)

Get Comprehensive Insights into the Market’s Size and Growth Trends

downloadDownload FREE Sample

Key Findings

  • Market Driver: Increasing respiratory disease management and home therapy requirements support device adoption, with an estimated 63% of modeled healthcare purchasing priorities emphasizing treatment accessibility, dependable equipment, and patient monitoring.
  • Major Market Restraint: Equipment costs, reimbursement limitations, and regulatory requirements constrain adoption, with an estimated 29% of modeled procurement concerns involving affordability, maintenance, and operational compliance.
  • Emerging Trends: Connected respiratory therapy, comfort-focused interfaces, and intelligent ventilation support are shaping innovation, with an estimated 42% of modeled development priorities directed toward usability and treatment optimization.
  • Regional Leadership: North America leads the modeled global market with 36% share, supported by established healthcare infrastructure, respiratory disease management programs, and substantial home therapy demand.
  • Competitive Landscape: ResMed Inc. leads the indicative supplier comparison with 18% share, reflecting its established positive airway pressure technology, mask portfolio, and connected home respiratory care capabilities.
  • Market Segmentation: Respiratory Positive Airway Pressure Devices lead the modeled product distribution with 24% share, while Hospitals dominate applications with 49% through critical care equipment and clinical respiratory support.
  • Recent Development: Respiratory device innovation increasingly emphasizes clinical workflow flexibility and patient comfort, with an estimated 37% of modeled new product priorities focused on adaptable therapy delivery and interface improvements.

Connected respiratory treatment and intelligent device features represent important developments across the Respiratory Devices Market. An estimated 42% of modeled technology priorities involve treatment usability, digital monitoring, and more adaptable respiratory support. Positive airway pressure devices increasingly incorporate connectivity functions that help patients and healthcare providers review therapy information where supported. Manufacturers are also improving interfaces to reduce discomfort associated with extended mask use. ResMed Inc. introduced the AirTouch F30i Comfort mask during February 2026, featuring a fabric-based design intended to improve the user experience during prescribed CPAP therapy. 

Portable respiratory equipment, advanced patient circuits, and lower-impact inhaler technologies are also attracting attention. An estimated 34% of modeled product modernization priorities involve convenient operation, treatment flexibility, and improved material efficiency. Vapotherm Inc. received clearance during April 2026 for its All Patient Circuit, supporting a wider range of patient sizes through a compatible high-velocity therapy platform. Chiesi Farmaceutici S.P.A. obtained European authorization for a triple therapy delivered through its NEXThaler dry powder inhaler during July.

Respiratory Devices Market Dynamics

Driver

"Growing respiratory care needs support hospital and home device adoption."

Increasing demand for respiratory treatment remains an important driver of equipment investment. An estimated 63% of modeled healthcare purchasing priorities involve treatment availability, reliable device performance, and effective patient support. Respiratory devices are used in managing conditions that can require assisted ventilation, prescribed oxygen, inhaled medication, or positive airway pressure therapy. Hospitals maintain different equipment categories according to emergency, intensive care, and routine clinical requirements.

Sleep apnea care and long-term respiratory support further strengthen demand for selected device categories. An estimated 47% of modeled home therapy purchasing priorities involve patient comfort, treatment adherence, and convenient equipment management. Positive airway pressure devices are commonly prescribed for suitable sleep-disordered breathing conditions, while oxygen concentrators support patients who require supplemental oxygen. Equipment choice depends on clinical assessment rather than consumer preference alone. Comfortable masks and understandable device interfaces can help patients follow treatment instructions.

Restraint

"Equipment affordability and regulatory obligations constrain healthcare purchasing."

Respiratory equipment costs and reimbursement conditions can restrict purchasing decisions across healthcare settings. An estimated 29% of modeled procurement concerns involve device affordability, servicing expenses, and regulatory compliance. Ventilators, oxygen delivery systems, and advanced monitoring accessories may require substantial initial investment and continuing maintenance. Hospitals must consider the availability of trained clinical personnel and consumable components. Home care providers face additional challenges involving insurance coverage, replacement schedules, and patient education. Medical devices also require appropriate regulatory authorization before entering designated markets.

Safety-related corrective actions and product quality concerns create further barriers to adoption. An estimated 25% of modeled supplier risk priorities involve device reliability, corrective maintenance, and regulatory surveillance. Respiratory devices interact directly with patients and may be used continuously during clinically important treatments. Malfunctioning components can therefore create serious consequences. During 2026, regulatory records documented recalls involving selected ventilator breathing circuits and positive airway pressure equipment, demonstrating the importance of post-market monitoring. Healthcare organizations must respond appropriately to manufacturer notices and regulatory instructions. 

Opportunity

"Home respiratory care and portable treatment create expansion opportunities."

Growing availability of appropriately supervised home respiratory therapy creates opportunities for equipment manufacturers and service providers. An estimated 41% of modeled commercial development priorities concern portable technology, accessible treatment interfaces, and reliable home support. Positive airway pressure devices, nebulizers, and prescribed oxygen concentrators can serve patients outside hospitals when clinically appropriate. Equipment must combine dependable performance with manageable maintenance requirements. Manufacturers increasingly improve portability and simplify controls while retaining necessary safety functions. Digital therapy records may support follow-up discussions between patients and healthcare professionals.

Hospital respiratory technology modernization creates additional opportunities for advanced products and specialized suppliers. An estimated 36% of modeled institutional investment priorities involve clinical workflow efficiency, adaptable respiratory support, and equipment replacement. Hamilton Medical AG continues developing ventilation technologies designed for different critical and emergency care environments. Vapotherm Inc. has expanded its patient circuit capabilities to support appropriate treatment across additional age groups.

Challenge

"Clinical compatibility and maintenance requirements complicate respiratory device deployment."

Maintaining dependable operation across different respiratory treatment environments remains a significant industry challenge. An estimated 28% of modeled engineering concerns involve equipment compatibility, therapy reliability, and clinical workflow integration. Respiratory products vary considerably in their intended uses, technical requirements, and patient populations. A mask designed for one positive airway pressure system may not be appropriate for every device configuration. Ventilator circuits and oxygen delivery accessories also require compatible components. Healthcare teams must assess operating instructions, approved configurations, and patient requirements before combining equipment. Incorrect setup can compromise treatment performance.

Infection prevention and ongoing equipment maintenance present additional challenges. An estimated 24% of modeled operational concerns involve cleaning procedures, component replacement, and dependable technical support. Respiratory devices may contain patient-contact components or internal systems requiring manufacturer-specified care. Reusable accessories need suitable reprocessing where permitted, while single-use components must be handled according to their labeling. Hospitals also need dependable inspection schedules and replacement inventories. Home users require clear instructions for routine care and identification of equipment problems.

Respiratory Devices Market Segmentation

Global Respiratory Devices Market Size, 2035

Get Comprehensive Insights on the Market Segmentation in this Report

download Download FREE Sample

By Types

Respiratory Positive Airway Pressure Devices: Respiratory Positive Airway Pressure Devices deliver controlled positive pressure to support appropriate treatment of sleep-disordered breathing and selected other respiratory conditions. The segment leads modeled product demand with 24% share, reflecting established CPAP and related therapy requirements. Manufacturers prioritize dependable pressure delivery, manageable noise, suitable humidification, and compatible mask connections. Connected features may help support adherence monitoring when properly implemented. ResMed Inc., BMC Medical Co., Ltd., and other supplied companies participate in this product category. Treatment settings must be established according to clinical instructions. 

Respiratory Mask: Respiratory Mask products provide patient interfaces for positive airway pressure and other compatible respiratory systems. The segment represents an estimated 16% of modeled product demand, supported by replacement requirements and patient comfort improvements. Masks vary in coverage, cushion material, and intended use, making correct fitting essential. ResMed Inc. introduced the AirTouch F30i Comfort during 2026 to expand fabric-based full-face mask options. Healthcare providers assess seal quality, skin tolerance, and compatibility with prescribed devices. Manufacturers increasingly emphasize simplified adjustment and materials suited to extended use. Demand depends on therapy adherence, replacement schedules, and clinically appropriate interface selection.

Respiratory Ventilators: Respiratory Ventilators provide mechanical assistance or support for patients requiring controlled respiratory intervention. The category accounts for an estimated 14% of modeled demand, reflecting critical care, emergency transport, and specialized clinical applications. Hamilton Medical AG, Medtronic PLC, and GE Healthcare maintain relevant respiratory technology expertise or established equipment portfolios. Modern ventilators incorporate monitoring functions and adjustable therapy controls according to intended clinical use. Healthcare organizations consider patient categories, staff training, equipment servicing, and compatible breathing circuits. Procurement depends on intensive care capacity and replacement needs.

Respiratory Oxygen Concentrators: Respiratory Oxygen Concentrators provide supplemental oxygen by concentrating oxygen from ambient air through suitable equipment systems. The category represents an estimated 13% of modeled product demand, supported by prescribed oxygen therapy in clinical and home settings. Invacare Corporation and Devilbiss Healthcare LLC have relevant experience within oxygen therapy equipment. Product selection depends on prescribed flow requirements, device capability, portability, and maintenance needs. Concentrators require suitable power arrangements and correct operation. Portable models may support mobility for eligible users but are not appropriate for every oxygen prescription. Demand reflects access to long-term respiratory care and dependable equipment servicing.

Respiratory Inhalers: Respiratory Inhalers deliver prescribed medicines to the respiratory tract through compatible drug-device systems. This segment accounts for an estimated 12% of modeled product demand, reflecting treatment requirements involving asthma and chronic obstructive pulmonary disease. Chiesi Farmaceutici S.P.A., Cipla Inc., and other supplied companies participate in inhaled therapy development. Device categories include metered-dose and dry powder delivery systems, each requiring appropriate technique. Chiesi obtained additional regulatory authorization during 2026 for therapy delivered through its NEXThaler device. Commercial demand depends on prescribed medicines, patient training, and applicable approvals. Correct inhalation technique remains important for achieving intended treatment delivery.

Respiratory Resuscitators: Respiratory Resuscitators are used to provide temporary respiratory assistance in designated emergency and clinical situations. The segment represents an estimated 5% of modeled product demand, reflecting specialized emergency preparedness and hospital equipment requirements. Devices may include manually operated systems intended for use by trained personnel. Appropriate ventilation technique and compatibility with patient size are essential. Hospitals prioritize dependable materials, easy inspection, and availability of suitable accessories. Routine training and maintenance support emergency readiness. Demand depends on healthcare facility requirements and replacement of aging equipment.

Respiratory Nebulizers: Respiratory Nebulizers convert compatible liquid medications into inhalable aerosols according to their intended operating design. The category accounts for an estimated 8% of modeled product demand, supported by prescribed respiratory therapy across hospitals and home care. Omron Healthcare Inc. manufactures compressor and portable mesh nebulizer products for different treatment requirements. Device selection depends on medication compatibility, aerosol delivery characteristics, cleaning procedures, and patient ability. Manufacturers increasingly emphasize portability and convenient operation. Home users require clear instructions and appropriate maintenance. Demand reflects treatment access and the continued use of nebulized medicines where clinically indicated.

Respiratory Humidifiers: Respiratory Humidifiers help maintain appropriate moisture conditions in compatible respiratory therapy systems. The segment represents an estimated 5% of modeled product demand, reflecting use with selected ventilation, oxygen therapy, and positive airway pressure arrangements. Humidification requirements depend on the therapy and the patient's clinical needs. Hamilton Medical AG and other supplied manufacturers offer relevant accessories or integrated respiratory systems. Appropriate water handling, cleaning, and component compatibility are essential. Product development emphasizes controlled moisture delivery and practical maintenance. Demand is associated with replacement accessories and specialized clinical treatment.

Respiratory Oxygen Hoods: Respiratory Oxygen Hoods provide an enclosed delivery interface for appropriate oxygen therapy, including selected neonatal care applications. The category represents an estimated 3% of modeled product demand, reflecting specialized clinical use. Oxygen hoods require controlled gas delivery, monitoring, and supervision by qualified personnel. Device selection depends on patient size, oxygen requirements, and clinical protocols. Healthcare facilities evaluate compatibility with available gas supply and monitoring equipment. Manufacturers emphasize reliable construction and accessible clinical handling. Demand remains associated with neonatal respiratory care and replacement requirements in appropriate treatment facilities.

By Applications

Hospitals: Hospitals represent the largest application for respiratory devices because they manage emergency breathing support, intensive care ventilation, and numerous supervised respiratory treatments. The segment accounts for an estimated 49% of modeled application demand, reflecting the need for diverse equipment across clinical departments. Hospitals purchase ventilators, oxygen delivery devices, resuscitation equipment, nebulizers, and suitable patient interfaces. Procurement decisions consider clinical indications, reliability, infection prevention, regulatory authorization, and maintenance arrangements. 

Home Care: Home Care involves prescribed respiratory therapies delivered outside hospitals with appropriate clinical oversight and equipment support. The category represents an estimated 41% of modeled application demand, reflecting positive airway pressure therapy, oxygen concentrator use, and selected nebulizer treatments. Patients often prioritize comfort, clear instructions, and dependable access to replacement accessories. Connected devices may help healthcare professionals review certain treatment information when patients consent and systems are properly configured. 

Other End-Users: Other End-Users includes outpatient treatment facilities, emergency medical services, and additional authorized care environments beyond hospitals and home care. The category represents an estimated 10% of modeled demand, reflecting specialized equipment requirements across diverse healthcare services. Appropriate devices may support patient transport, clinic-based treatments, or supervised respiratory interventions. Purchasing decisions depend on intended use, staff competency, maintenance availability, and regulatory requirements. Compact equipment can improve deployment flexibility when clinically appropriate. Manufacturers increasingly provide products suited to defined operating environments. 

Respiratory Devices Market Regional Outlook

Global Respiratory Devices Market Share, by Type 2035

Get Comprehensive Insights into the Market’s Size and Growth Trends

download Download FREE Sample

North America

North America maintains a leading position in respiratory equipment through established healthcare infrastructure, sleep medicine services, and demand for home therapy. The region accounts for an estimated 36% of modeled global demand, supported by hospital procurement and extensive respiratory care requirements. The United States represents the largest regional market, with ResMed Inc., Vapotherm Inc., and other supplied companies offering relevant technologies. Healthcare facilities increasingly evaluate connected therapy platforms, equipment reliability, and clinically appropriate ventilation support. Product development includes improved mask interfaces and flexible respiratory circuits. Regulatory surveillance remains important, particularly for products used in critical clinical situations.

Europe

Europe represents an established market for respiratory treatment equipment through hospital respiratory services, sleep apnea management, and specialized pharmaceutical delivery systems. The region accounts for an estimated 27% of modeled global demand, supported by healthcare infrastructure and established regulatory frameworks. Hamilton Medical AG, Chiesi Farmaceutici S.P.A., and Koninklijke Philips N.V. maintain relevant industry capabilities. European manufacturers increasingly evaluate patient comfort, environmental performance, and clinical usability. Chiesi's authorization for NEXThaler-delivered triple therapy demonstrates continuing inhaler innovation. Healthcare providers emphasize qualified equipment, patient education, and dependable technical support.

Asia-Pacific

Asia-Pacific is an important growth market for respiratory devices through healthcare infrastructure development, expanding respiratory treatment access, and increasing manufacturing capabilities. The region represents an estimated 26% of modeled global demand, supported by hospitals and home care services across major economies. China, India, Japan, and other countries contribute to different parts of the respiratory equipment value chain. BMC Medical Co., Ltd., Omron Healthcare Inc., and Cipla Inc. maintain relevant product or treatment capabilities. Regional demand includes positive airway pressure equipment, nebulizers, and hospital respiratory support systems. Purchasing conditions vary with healthcare access, affordability, and local regulatory requirements.

Middle East and Africa

Middle East and Africa represents a developing respiratory equipment market through hospital investment and improvements in specialized healthcare services. The region accounts for an estimated 7% of modeled global demand, reflecting infrastructure expansion and uneven access to advanced treatment. Hospitals increasingly evaluate reliable ventilation and oxygen delivery equipment for critical care requirements. Home respiratory therapy adoption depends on appropriate prescription pathways and access to maintenance services. International manufacturers frequently rely on authorized distributors and local technical partners. Procurement priorities include product durability, staff training, and availability of consumables.

Rest of World

Rest of World includes additional respiratory equipment markets across Latin America and smaller healthcare economies. The region represents an estimated 4% of modeled global demand, reflecting developing clinical infrastructure and varied purchasing capacity. Hospitals require suitable emergency respiratory equipment, while home care demand depends on treatment access and reimbursement conditions. Manufacturers increasingly evaluate distribution partnerships and regional equipment servicing. Availability of trained personnel remains important for complex respiratory technologies.

List of Top Respiratory Devices Market Companies

  • Hamilton Medical AG
  • TotalCare eHealth
  • Curative Medical Inc.
  • Acorda Therapeutics, Inc.
  • Pulmatrix Inc.
  • ResMed Inc.
  • 3b Medical, Inc.
  • Invacare Corporation
  • Medtronic PLC
  • Gilbert Technologies BV
  • Respira Therapeutics, Inc.
  • Adamis Pharmaceuticals Corporation
  • Mylan N.V.
  • Devilbiss Healthcare LLC
  • Chiesi Farmaceutici S.P.A.
  • Chart Industries, Inc.
  • Cipla Inc.
  • GE Healthcare
  • Whole You, Inc.
  • BMC Medical Co., Ltd.
  • PMD Device Solutions Limited
  • Teicos Pharma Ltd.
  • Viroblock Sa
  • H&T Presspart Manufacturing Ltd.
  • Orion Corporation
  • Vapotherm Inc.
  • Koninklijke Philips N.V.
  • Circadiance LLC
  • Omron Healthcare Inc.

Top Two Companies with Highest Market Share

  • ResMed Inc.: An indicative 18% share within the modeled competitive comparison, supported by positive airway pressure devices, mask innovation, connected therapy solutions, and established home respiratory care distribution.
  • Hamilton Medical AG: An indicative 12% share within the modeled competitive comparison, reflecting specialized ventilation technologies, emergency respiratory systems, and international clinical equipment capabilities.

Investment Analysis and Opportunities

Respiratory device investment increasingly emphasizes dependable home therapy, clinical equipment modernization, and adaptable patient interfaces. An estimated 38% of modeled investment priorities concern patient comfort, connected functionality, and treatment reliability. Manufacturers are developing devices that simplify routine operation while retaining necessary clinical safeguards. Hospitals evaluate ventilation systems according to patient requirements, maintenance support, and total ownership costs. 

Hospital respiratory support and lower-impact inhaler delivery represent additional opportunities. An estimated 31% of modeled investment priorities involve adaptable clinical equipment, inhaler innovation, and manufacturing quality improvements. Hamilton Medical AG and Vapotherm Inc. have introduced technologies addressing ventilation workflows and patient circuit flexibility. Chiesi Farmaceutici S.P.A. continues advancing inhaler formulations and lower-emission delivery systems.

New Product Development

New product development in respiratory care increasingly focuses on patient comfort, flexible treatment delivery, and dependable clinical operation. An estimated 37% of modeled innovation priorities involve improved therapy interfaces, adaptable patient circuits, and simplified respiratory device workflows. ResMed Inc.'s AirTouch F30i Comfort combines a fabric-based mask design with established positive airway pressure therapy requirements. Vapotherm Inc.'s All Patient Circuit extends compatible respiratory support across additional patient groups. Hamilton Medical AG introduced its HAMILTON-EM7 emergency ventilator, emphasizing practical deployment in designated clinical environments. 

Inhaler innovation increasingly combines drug delivery performance with environmental considerations. An estimated 33% of modeled product development priorities involve reliable aerosol delivery, device compatibility, and reduced environmental impact. Chiesi Farmaceutici S.P.A. received European authorization for an asthma maintenance therapy delivered through NEXThaler and advanced regulatory submissions for lower-impact inhaler propellants. These developments concern different delivery technologies and must be evaluated according to their approved indications.

Five Recent Developments

  • January 2026 – Cipla Inc.: Cipla launched its Breathefree Lung Wellness Center in Mumbai on January 27, expanding access to specialized respiratory diagnostic services. The facility offers more than 60 lung health assessments and supports clinical evaluation of respiratory conditions.
  • February 2026 – ResMed Inc.: ResMed introduced the AirTouch F30i Comfort full-face CPAP mask in the United States on February 11. Its fabric cushion and wrapped frame were designed to improve comfort and support consistent use of prescribed positive airway pressure therapy.
  • April 2026 – Vapotherm Inc.: Vapotherm announced FDA clearance for its All Patient Circuit on April 21. The compatible HVT 2.0 system can support prescribed therapy across a flow range of 2 to 45 liters per minute, extending its application from neonatal to adult patients.
  • May 2026 – Hamilton Medical AG: Hamilton Medical introduced the HAMILTON-EM7 emergency ventilator during RETTmobil 2026. The launch strengthened its portfolio of mechanical ventilation technology for emergency medical services and transport-related respiratory support.
  • July 2026 – Chiesi Farmaceutici S.P.A.: Chiesi announced European marketing authorization on July 31 for its single-inhaler triple therapy delivered through the NEXThaler dry powder inhaler. The authorization covers maintenance treatment of asthma in adults under the approved prescribing conditions.

Future Outlook

The Respiratory Devices Market is expected to develop through increasing requirements for dependable clinical respiratory support, accessible home therapy, and improved patient treatment experiences. Hospitals will continue prioritizing reliable ventilation equipment and oxygen delivery systems, while home care providers will emphasize suitable positive airway pressure devices, concentrators, and medication delivery technologies. Manufacturers will increasingly focus on comfortable patient interfaces, simplified administration, and dependable digital support features. 

Competition will increasingly reflect the ability to combine technical reliability with patient-centered design and responsible manufacturing practices. North America will remain important through established healthcare infrastructure, while Europe and Asia-Pacific will contribute substantial demand and product innovation. Companies including ResMed Inc., Hamilton Medical AG, Vapotherm Inc., Chiesi Farmaceutici S.P.A., and Omron Healthcare Inc. will continue participating in different respiratory technology categories. Suppliers that deliver clinically suitable products, accessible training, and reliable service support will be better positioned to address evolving healthcare requirements.

Respiratory Devices Market Report Coverage

REPORT COVERAGE DETAILS

Market Size Value In

USD 31755.97 Million in 2026

Market Size Value By

USD 56211.56 Million by 2035

Growth Rate

CAGR of 6.55% from 2026-2035

Forecast Period

2026 - 2035

Base Year

2025

Historical Data Available

Yes

Regional Scope

Global

Segments Covered

By Type :

  • Respiratory Positive Airway Pressure Devices
  • Respiratory Mask
  • Respiratory Ventilators
  • Respiratory Oxygen Concentrators
  • Respiratory Inhalers
  • Respiratory Resuscitators
  • Respiratory Nebulizers
  • Respiratory Humidifiers
  • Respiratory Oxygen Hoods

By Application :

  • Hospitals
  • Home Care
  • Other End-Users

To Understand the Detailed Market Report Scope & Segmentation

download Download FREE Sample

Frequently Asked Questions

The global Respiratory Devices Market is expected to reach USD 56211.56 Million by 2035.

The Respiratory Devices Market is expected to exhibit a CAGR of 6.55% by 2035.

Hamilton Medical AG, TotalCare eHealth, Curative Medical Inc., Acorda Therapeutics, Inc., Pulmatrix Inc., ResMed Inc., 3b Medical, Inc., Invacare Corporation, Medtronic PLC, Gilbert Technologies BV, Respira Therapeutics, Inc., Adamis Pharmaceuticals Corporation, Mylan N.V., Devilbiss Healthcare LLC, Chiesi Farmaceutici S.P.A., Chart Industries, Inc., Cipla Inc., GE Healthcare, Whole You, Inc., BMC Medical Co., Ltd., PMD Device Solutions Limited, Teicos Pharma Ltd., Viroblock Sa, H&T Presspart Manufacturing Ltd., Orion Corporation, Vapotherm Inc., Koninklijke Philips N.V., Circadiance LLC, Omron Healthcare Inc.

In 2026, the Respiratory Devices Market value will reach at USD 31755.97 Million.

faq right

Our Clients

Captcha refresh

Trusted & Certified